| Literature DB >> 29697883 |
Dominic Carlin1,2, Ben Babourina-Brooks1,2, Nigel P Davies2,3, Martin Wilson2,4, Andrew C Peet1,2.
Abstract
BACKGROUND: Metabolite concentrations are fundamental biomarkers of disease and prognosis. Magnetic resonance spectroscopy (MRS) is a noninvasive method for measuring metabolite concentrations; however, quantitation is affected by T2 relaxation.Entities:
Keywords: MRS; MRS quantification; T2 relaxation; pediatric brain tumors
Mesh:
Substances:
Year: 2018 PMID: 29697883 PMCID: PMC6492201 DOI: 10.1002/jmri.26054
Source DB: PubMed Journal: J Magn Reson Imaging ISSN: 1053-1807 Impact factor: 4.813
Figure 1Example spectra from (a) pilocytic astrocytoma astrocytoma and (b) medulloblastoma at short‐ and long‐TE with TARQUIN fits (red) and fit residuals shown beneath the spectra.
Figure 2Example spectra from (a) basal ganglia and (b) white matter at short‐ and long‐TE with TARQUIN fits (red) and fit residuals shown beneath the spectra.
Figure 3Mean (standard error) T2s of tNAA, tCho, tCr, and water for pilocytic astrocytomas, medulloblastomas, basal ganglia, and normal white matter. *P < 0.05, **P < 0.001.
Estimated Metabolite T2 Relaxation Times (msec) in Pilocytic Astrocytoma, Medulloblastoma, Basal Ganglia (BG), and White Matter (WM)
| T2 relaxation time (msec) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
| Medulloblastomas | BG | WM | |||||
| Mean SD |
| Mean SD |
| Mean SD |
| Mean D |
| |
| tNAA | 191 ± 56 | 10 | 333 ± 124 | 5 | 436 ± 140 | 16 | 423 ± 113 | 14 |
| tCho | 372 ± 176 | 11 | 587 ± 143 | 9 | 344 ± 122 | 14 | 313 ± 154 | 15 |
| tCr | 217 ± 65 | 8 | 305 ± 51 | 9 | 225 ± 78 | 16 | 237 ± 72 | 10 |
| Water | 181 ± 35 | 11 | 123 ± 45 | 10 | 90 ± 9 | 16 | 86 ± 8 | 15 |
Figure 4Mean ± standard error metabolite concentrations (mM) in (a) pilocytic astrocytoma, (b) medulloblastoma, and (c) normal brain estimated at short‐TE. Metabolite concentrations are corrected for relaxation effects using either default TARQUIN relaxation correction; literature T2 values; a metabolite T2 of 400 msec and a patient measured water (IW) T2; or the average metabolite (AM) T2 for that tissue type and IW T2. *P < 0.05, **P < 0.01.
Root Mean Square Percentage Difference Between Metabolite Concentrations Corrected Using Different Combinations of T2 Relaxation Times (see Materials and Methods) Compared to the Corrected Concentration Using the Patient's Measured T2 Values (AM, IW)
| Pilocytic astrocytoma | |||
|---|---|---|---|
| Default | Literature | 400, IW | |
| Short TE singlets | 31.1 | 5.5 | 6.0 |
| Long TE singlets | 46.4 | 19.8 | 26.1 |
A, average; I, individual; M, metabolite; W, water.
Estimated Mean ± SD Metabolite Concentrations (mM) of Pilocytic Astrocytomas, Medulloblastomas, and Normal Brain, Corrected for Individually Estimated Water and Average Metabolite T2 Relaxation Times
| Concentration (mM) | ||||||
|---|---|---|---|---|---|---|
| Pilocytic astrocytomas | Medulloblastomas | Normal | ||||
| ANOVA all groups ( | Mean SD | Mean SD | Pilocytic astrocytoma Vs. medulloblastoma ( | Mean SD | Normal vs. all tumors ( | |
| tNAA | 10−6 | 1.62 ± 0.66 | 1.25 ± 1.35 | 0.36 | 7.44 ± 4.45 | 10−7 |
| tCho | 10−9 | 1.20 ± 0.40 | 5.50 ± 2.24 | < 0.001 | 1.62 ± 0.64 | < 0.01 |
| tCr | 10−7 | 0.86 ± 0.61 | 3.74 ± 2.28 | < 0.01 | 5.69 ± 2.10 | 10−6 |
| Lac | 10−7 | 1.35 ± 0.59 | 4.03 ± 2.47 | 0.01 | 0.32 ± 0.97 | 10−6 |
| Ala | 0.06 | 0.29 ± 0.36 | 0.30 ± 0.46 | 0.73 | 0.12 ± 0.17 | 0.02 |
| mI | 0.15 | 1.12 ± 1.14 | 3.08 ± 3.13 | 0.17 | 3.48 ± 3.72 | 0.09 |
| Tau | 10−7 | 0.65 ± 0.47 | 4.39 ± 2.19 | < 0.001 | 0.98 ± 1.23 | < 0.01 |
| Gly | 10−10 | 0.33 ± 0.54 | 4.15 ± 1.87 | < 0.001 | 0.42 ± 0.62 | < 0.001 |
| Scy | 10−5 | 0.00 ± 0.00 | 0.65 ± 0.51 | < 0.01 | 0.19 ± 0.14 | 0.25 |
| Glx | < 0.01 | 5.22 ± 2.59 | 5.20 ± 2.75 | 0.95 | 7.75 ± 3.95 | < 0.001 |